Breaks Categories: News

MondaySep 27, 2021 12:34 pm

BioMedNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Enters Strategic Commercial Agreement with UK Licensee

Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced its entry into a global commercial contract with MySugarWatch DuoPack Limited (“MSW-DP”). Under the agreement, the continuous glucose monitor (“CGM”) and sensors will be provided as duo packs with prescription only medicines that are widely prescribed for people with type 2 diabetes. MSW-DP has been granted global rights to the sugarBEAT(R) non-invasive CGM devices and sensors, to be provided solely as duo packs with these medicines, under the terms of the agreement, which Nemaura will…

Continue Reading

FridaySep 24, 2021 12:54 pm

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Release FY 2021 Financial Report and Corporate Update

InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing and clinical development of rare cannabinoids, has released its financial results and corporate update for FY 2021. In addition, the company announced a conference call and webcast, in which company leadership will discuss the report. Interested parties can access a replay of the webcast for 90 days. Corporate highlights of the report include the definitive agreement the company entered to acquire BayMedica Inc., a private company specializing in the manufacture and commercialization of rare cannabinoids; the announcement that INM’s IntegraSyn(TM) cannabinoid manufacturing approach had achieved a level of 2g/L cannabinoid yield,…

Continue Reading

ThursdaySep 23, 2021 9:54 am

BioMedNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Forms Medical Consortium to Advance OSA Technology

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild to moderate obstructive sleep apnea (“OSA”), today announced the official formation of the Vivos Medical Consortium. According to the update, this physician working group, led by Drs. Clete Kushida of Stanford University and Cecilia Wu of the University of Alberta, will collaborate to advance Vivos’ OSA technology capabilities. “Every specialty in medicine deals with the negative impact of obstructive sleep apnea in some way, with the end stage of untreated sleep apnea including diminished quality of life,…

Continue Reading

WednesdaySep 22, 2021 2:26 pm

BioMedNewsBreaks – RYAH Group Inc. (CSE: RYAH) to Present at Wall Street Reporter’s ‘Next Super Stock’ Livestream Conference

RYAH Group (CSE: RYAH) today announced that its Chief Executive Officer Gregory Wagner will be presenting at Wall Street Reporter's "Next Super Stock" livestream conference on Thursday, Sept. 23, 2021. The online event is expected to give the investment community and existing shareholders an opportunity to interact in real time with Wagner and learn about the company and its operations. Wagner’s presentation is scheduled to begin at 1:00 ET on the day of the conference, during which he will highlight RYAH’s experience and mission, and, time permitting, open the floor for questions. Interested parties should visit https://ibn.fm/K0MtA to ensure access…

Continue Reading

WednesdaySep 22, 2021 2:08 pm

BioMedNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces Submission of IND Application for Eating Disorders Clinical Trial

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, has submitted an Investigational New Drug ("IND") application to the U.S. Food and Drug Administration ("FDA"). The clinical trial is designed to evaluate the efficacy of TRYP’s clinical candidate, TRP-8802, for the treatment of patients with eating disorders. TRYP is working with Jennifer Miller, MD, from the University of Florida, to conduct the trial as well as evaluate its oral formulation of synthetic psilocybin, TRP-8802, in combination with psychotherapy. The IND application outlines specifics in regard to the safety of…

Continue Reading

WednesdaySep 22, 2021 12:30 pm

BioMedNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) to Present at Benzinga Healthcare Small Cap Conference

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild to moderate obstructive sleep apnea (“OSA”), today announced that its chairman and CEO Kirk Huntsman and CFO Brad Amman will be presenting at the online Benzinga Healthcare Small Cap Conference at 2:20 pm ET on Wednesday, Sept. 29, 2021. The event is scheduled to take place from Sept. 29-30, 2021. Investors interested in joining the Vivos presentation should visit https://ibn.fm/JFY3h to register for a free spectator pass. A replay of the presentation will be available for view…

Continue Reading

FridaySep 17, 2021 12:33 pm

BioMedNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Names World-Renowned Thought Leader as Advisory Board Member

Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing noninvasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, announced that Dr. Osama Hamdy, MD, PhD, has joined its advisory board. Hamdy will act as a consultant and will provide invaluable input regarding key opinion leader studies in both the diabetes and metabolic health fields using Nemaura’s glucose monitoring technology. An acclaimed endocrinologist, Hamdy is medical director of the Obesity Clinic Program at the Joslin Diabetes Center; he is also an associate professor of medicine at Harvard Medical School. He has built a stellar reputation as…

Continue Reading

FridaySep 17, 2021 12:09 pm

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM), BayMedica Slated to Participate in Tribe Public Webinar

InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing and clinical development of rare cannabinoids, has announced that its CEO Eric A. Adams will be a featured presenter at Tribe Public’s upcoming complimentary ZOOM presentation titled “Accelerating The Commercialization of Rare Cannabinoids.” The webinar is scheduled to begin on Sept. 21, 2021, at 11.30 a.m. ET. In addition to Adams, BayMedica Inc. cofounder Shane Johnson will also present during the event. Adams and Johnson’s presentation will be hosted by Tribe Public managing member John F. Heerdink Jr., who will field live questions and pass those on to the presenters. In…

Continue Reading

FridaySep 17, 2021 9:56 am

BioMedNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) Exec to Participate in Upcoming in Mental Health Virtual Conference

Mind Cure Health (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH), a leader in advanced proprietary technology and research for psychedelics, has announced that president and CEO Kelsey Ramsden will be participating in the Advances in Mental Health Virtual Conference. The one-day conference, presented by Maxim Group LLC and hosted by M-Vest, is scheduled for Sept. 22, 2021. Ramsden will be a panel member in two separate sessions held during the virtual event. The panels, which are part of the “Disruptors in the Mental Health Space” series, are titled “The Second Generation – Beyond Psilocybin and MDMA”and “Delivery, Manufacturing and Technology” and will…

Continue Reading

ThursdaySep 16, 2021 9:35 am

BioMedNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) Announces Partnership Digital Therapeutics Alliance

Mind Cure Health (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH), a leader in advanced proprietary technology and research for psychedelics, is joining the Digital Therapeutics Alliance. A nonprofit association of industry leaders, the alliance is dedicated to driving awareness and adoption of digital therapies. MINDCURE announced that, as part of the alliance, the company is committed to providing value and reimbursement, policy and regulation, and awareness to educate the broader health-care industry about the benefits of including new technologies in current treatment regimes. Collaboration with the alliance is a strategic move as MINDCURE works to position iSTRYM, its proprietary software application, as…

Continue Reading